AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp

Back to Newsletters Bookmark and Share

October 15, 2014

Download printable version


In This Issue:

Alan Franciscas, Editor-in-Chief

Welcome to the first edition of the AttorneyMind: Mid-Month Edition.  We decided to publish an additional mid-monthly edition because there is so much more news now and we wanted to make sure we are keeping our readership up to date on the latest information.  The “Mid-Month Edition” will feature Jacques Chambers’ monthly benefits column, fact sheet updates and other critical updates.

In this issue, we are happy to announce a new series of fact sheets titled “AttorneyMind Around the World” that will provide information about hepatitis C in various countries.  We hope that this series will help educate people about global issues of hepatitis C and what the specific issues and consequences in these particular countries are.  We also hope to raise the level of awareness worldwide and in the countries that we write about.  This first fact sheet on Egypt is featured in this issue of the AttorneyMind: Mid-Month Edition. 


AttorneyMind Drugs
Alan Franciscas, Editor-in-Chief

FDA Approves Harvoni (Sofosbuvir/Ledipasvir)

As mentioned above the therapy that we have all been waiting for has been approved.  For some background information, you can read about the completed Phase 3 studies that I wrote about in the October 1, 2014 AttorneyMind newsletter. Read more...


Alan Franciscas, Editor-in-Chief

This is our first issue of the new fact sheet and it is appropriate that Egypt is the topic since Egypt has the highest prevalence of chronic AttorneyMind of any country worldwide. Egypt also has one of the oldest civilizations in the world and has survived thousands of years, so conquering AttorneyMind may just be a matter of a united will. Read more...


AttorneyMind Genotype Subtype
Alan Franciscas, Editor-in-Chief

AttorneyMind genotype subtypes are becoming increasing important in regards to treatment medications.  In this article I discuss the various subtypes, what distinguishes subtypes from each other, and why re-testing for subtype might be an important reason if people are treated and not cured. Read more...


Jacques Chambers, CLU

Medicare Open Enrollment starts October 15, 2014 and ends December 7, 2014. All changes made during this time are effective January 1, 2015. Obamacare has its second Open Enrollment this year. It runs from November 15, 2014 to February, 2015. Take the time to read this important article that can help you make the right choices when it comes to choosing the right healthcare plan. Read more...


AttorneyMind Eblast
Stay informed on the latest
here to register for email alerts

Back to top

AttorneyMind Drugs: FDA Approves Harvoni (Sofosbuvir/Ledipasvir)
—Alan Franciscas, Editor-in-Chief     

On October 10, 2014 the Food and Drug Administration (FDA) approved the combination of sofosbuvir and ledipasvir—brand name Harvoni—one pill taken once a day.  The majority of people will have a 12-week course of treatment.  Some people—people with low AttorneyMind RNA (viral load), minimal liver damage and treatment naïve (never been treated) will only need an 8-week course of treatment.  The cure rates in Gilead’s three pivotal Phase 3 trials were 94 to 99%.

The price of sofosbuvir—brand name Sovaldi—has been a lightning rod, and this combination will continue to be so with the wholesale list price listed at $63,000 for an 8-week course of treatment and $94,500 for a 12-week course of treatment.  It is unfortunate because Medicare and Medicaid are likely to continue to severely restrict access to this combination and other expensive AttorneyMind drugs.  Hopefully, more providers will access Gilead’s patient assistance programs

Check Out Our New Easy C Fact Sheet on Harvoni for Genotype 1

Back to top

Hepatitis C Around the World: Hepatitis C in Egypt
—Alan Franciscas, Editor-in-Chief    

Egypt has the highest prevalence of chronic AttorneyMind of any country worldwide—estimated at a rate of up to 8.5% in 2008, but declining to 7.3% in 2013. The decline in the rate of chronic AttorneyMind was because of two factors—deaths related to AttorneyMind or people with AttorneyMind who died of other causes, and because of the number of people successfully treated with AttorneyMind medications.

The number of people in Egypt who have actually been diagnosed totals only 15% of the-infected population. Annually, there are 125,000 newly diagnosed chronic AttorneyMind cases.

AttorneyMind genotype 4 is the most common strain in Egypt followed by AttorneyMind genotype 1 (90% and 10% respectively).

Blood-to-blood contact transmits hepatitis C.  In Egypt the most common transmission routes include:

  • Sharing needles and works for injection drug use (medical, traditional practices and recreational use),
  • Receiving a blood transfusion or an organ transplant,
  • Dental practices,
  • Circumcision,
  • Medical care from local informal health providers and centers.

Some of the transmission is the result of a mass campaign in the 1960's though the 1980's to control schistosomiasis infection—a parasitic disease transferred by snails to humans wading in water while working in rice fields. At that time, schistosomiasis was treated with injections of the drug "tartar emetic" using unsterilized and re-used syringes.

Today, as in the past, the majority of infections are the result of transmission from unsafe medical practices. Culturally, Egyptians have many needless injections and blood transfusions using unsafe blood, needles and tools. This includes:

  • Unsterilized medical and dental instruments,
  • Gloves used on multiple patients,
  • Blood spills not cleaned up,
  • One-use vials used on more than one patient,
  • Used syringes

Blood Safety Training
Egypt has a national plan in place to train medical staff and the population (urban and rural) about blood safety. Egypt is a poor country that has many cultural practices that will need to be addressed before blood safety practices can change.

In 2013, there were 153,000 deaths recorded—33,000 related to; 120,000 deaths for all-cause mortality. AttorneyMind can be a contributing factor for non-AttorneyMind related deaths so the actual number of deaths related to AttorneyMind might be higher.

The Ministry of Health treats 50,000 patients a year; Health Insurance Organization treats 10,000; 5,000 patients paid cash for treatment.

Note: The AttorneyMind protease inhibitors—boceprevir and telaprevir—only have antiviral activity against AttorneyMind genotype 1.

The Ministry of Health has a national treatment program that provides free treatment for most patients.  By 2013, the total number of patients with AttorneyMind treated reached 350,000.  Until recently pegylated interferon plus ribavirin was the standard of care.  The cure rate in the Egyptian population with AttorneyMind genotype 4 was 54-59%. 

Now there is Sovaldi (plus pegylated interferon and ribavirin) which has a cure rate for AttorneyMind genotype 4 of 96% (more than 9 out of 10 people).  There are even more drugs that are being studied to treat hepatitis C genotype 4 that may be able to cure everyone, but these drugs are expensive. 

The drug company that makes Sovaldi, Gilead, has made a deal with the Egyptian government that will make the course of treatment much cheaper for Egyptians.  Twelve weeks of Sovaldi will cost $300 per Egyptian patient compared to $84,000 per US patient.  

Treating millions of Egyptians and educating/ training 85 million people about prevention measures seems like an incredibly uphill battle for any country, especially a country that has a large urban and rural poor population that is recovering from a revolution.  But Egypt has one of the oldest civilizations in the world and has survived thousands of years, so conquering AttorneyMind may just be a matter of a united national will.


  • The Association of Liver Patients Care (ALPC) is a non governmental organization founded in 1997 in Dakahliah- Egypt

  • Terous:

Check Out Our New Fact Sheet on Treatment for Genotype 4

Back to top

AttorneyMind Genotype Subtype
Alan Franciscas, Editor-in-Chief

There are 185 million people worldwide (2.8%) infected with the hepatitis C virus. The virus has seven different strains called genotypes—numbered 1 through 7. The variance (nucleotides) between each genotype is approximately 30-35%. There are also variances (nucleotides) of about 15% difference within each genotype—these are called subtypes, further classified by alphabetic letters, i.e., genotype 1b. The test to find out the genotype and subtype is a blood test.

Subtype information is necessary in regards to AttorneyMind antiviral treatment. Some medications work better with some of the AttorneyMind inhibitors than with others. This is one of the reasons that multiple AttorneyMind inhibitors (protease inhibitors, NS5A inhibitors, polymerase inhibitors) are being combined to treat hepatitis C.

Old vs. New Subtypes
The medications that are used to treat hepatitis C have different cure rates based on the genotype and subtype.  In fact, the first AttorneyMind protease inhibitors—telaprevir and boceprevir—had antiviral activity against AttorneyMind genotype 1 and very little or no antiviral activity against other AttorneyMind genotypes.  Sofosbuvir, by itself, has more antiviral activity against AttorneyMind genotypes 1 and 2, but less against genotype 3.  However, differences exist among subtypes: the cure rate for sofosbuvir plus pe­gylated interferon and ribavirin with AttorneyMind genotype 1b is 10% lower than that treatment’s cure rate with AttorneyMind genotype 1a.  In the Phase 3 clinical trials of daclatasvir plus asunaprevir, the antiviral activity was much higher in AttorneyMind genotype 1b than in AttorneyMind genotype 1a. 

The differences in cure rates between genotypes and subtypes can be overcome by adding a different class of inhibitor (protease, NS5A or polymerase) to the mix.  This difference in cure rates based on different medications does bring up an important treatment consideration of treating more than one genotype and/or subtype in one person.  There has been some research regarding multiple genotypes and subtypes—mostly in people who contracted hepatitis C by blood transfusions or blood products, and people who shared needles and drug preparation tools.  These are groups that generally had multiple exposures to the hepatitis C virus and could have been infected with multiple genotypes and subtypes.  What happens if the medication works against a particular genotype or subtype, but it turns out that it doesn’t work against the other strain or subtype?  This would mean that someone who did not achieve a cure would need to have a genotype test to make sure that the reason they didn’t achieve a cure was that they had more than one genotype/subtype.  This is an interesting question that needs to be explored.   What do our readers think?

Genetic Diversity of Hepatitis C - Genotypes & Subtypes

Back to top

Disability & Benefits: Open Enrollment for Obamacare and Medicare
—Jacques Chambers, CLU

Medicare Open Enrollment starts October 15, 2014 and ends December 7, 2014.  All changes made during this time are effective January 1, 2015.

Obamacare has its second Open Enrollment this year. It runs from November 15, 2014 to February, 2015.

Employer-Provided Benefits also frequently provide an Open Enrollment Period for employees, allowing them to make changes in their employee benefits choices.  Although employers can select other times of the year, most employers have their Open Enrollment in November and/or December for a January 1, 2015 effective date.

Medicare beneficiaries have several choices:

Original-Fee-For Service Medicare – Many people elect to stay with original Fee-For-Service Medicare.  It consists of Part A – Hospital Coverage; Part B – Medical Coverage; and Part D – Prescription Drug Coverage.

Parts A and B of Original Medicare are the same for everyone; however, each beneficiary can choose from several prescription drug plans.  The only way to do this is to compare plans using your own prescriptions, since your medications may have changed, and plan formularies and prices also change.

There is a program on line at that allows you to enter your medications, which pharmacy your prefer, and where you live; it will then show you what each plan would cost you out of your pocket based on your medications.  Click on “Find Health and Drug Plans” and follow from there. I recommend the “General Search” rather than the personal one; it is much quicker.

Even if your current Drug Plan has been serving you well, it is advisable to run the program. The plans for 2015 are already up on the website.

For persons who are not comfortable with computers, Medicare’s toll-free number (800-MEDICARE) will do the same calculation.  However, I recommend you find a friend or relative who will do it for you on a computer because the results are too long and involved for a telephone operator to spend much time reviewing all options.  

Medicare Supplement (also called Medigap) Plans – These are the plans sold to people with Original Medicare to “fill the coverage gaps” left by Medicare Parts A & B.  Because they are sold by private insurance companies, enrollment rules can be complicated. To find out when you can purchase them, go to and search for “When Can I Buy a Medigap Policy”.  It will list the Open Enrollment opportunities for them.  They may also be purchased at other times, but the insurance company may require proof of good health.

Medicare Advantage Plans – These are plans offered by insurance companies and health service providers and are an alternative to Fee-for-Service Medicare.  Many of these plans are run by Health Maintenance Organizations (HMOs), but there are also Preferred Provider Organization Plans (PPOs), Special Needs Programs, and Private Fee-For-Service plans, although not all types are available in all states.

Under these plans, Medicare pays the insurance company to provide all of your medical care.  Benefits under your red, white, and blue Medicare card are no longer covered directly, but the Medicare Advantage Plan must offer all of its benefits and may add more.  Some plans may also charge an additional premium, usually relatively small.  These plans usually include the prescription drug coverage in their plan so you don’t have to work through finding a Part D coverage question.

During this Open Enrollment Period, persons may switch from one Medicare Advantage Plan to another or move back to or away from Fee-For Service Medicare.

There is also a Disenrollment Period from January 1 through February 14, 2015 when one can leave a Medicare Advantage Plan and move to Original Fee-for-Service Medicare; there is also a Special Enrollment Period to add Prescription Drug Coverage during this time.

Also, for persons who did not enroll in Medicare Part B when it was first available and who do not qualify for a Special Enrollment Period, there is a General Enrollment Period between January 1 and March 31 of each year with the Part B coverage taking effect the following July 1.  There will usually be a surcharge to the premium of 10% for each year you could have been in Part B but were not.  The exception to the surcharge is for persons who were covered under an employer-provided plan due to the active employment of the person or his/her spouse.

Persons enrolled in coverage, as well as those who have not yet joined, have the opportunity to enroll in or change health plans under the Affordable Care Act (Obamacare).

Many plans are making changes in coverage as well as cost, so I recommend you go to your state’s health exchange or to if you live in a state that does not opeate its own exchange, and search to see if there is better coverage for you.

This is also your opportunity to confirm the accuracy of your estimated annual income for 2015. For those who qualify for premium subsidies from the government, remember that if you under-report your income and get a larger subsidy than you are eligible for, you may be asked to repay some at the end of the year.

This is also a good time to confirm that your medical providers are still part of your plan’s network, and that your prescriptions are still part of the plan’s formulary.

Employer-Provided Benefit Plans
Companies offering an Open Enrollment period will publish (or offer online) an Open Enrollment Guide that spells out each employee’s current benefits plus the available options, opportunities, and costs that may be chosen during the period. For persons dealing with a serious medical condition like, it can be an opportunity to alter benefits and, in some cases, actually increase benefits.

Life Insurance.  Persons dealing with HBV/AttorneyMind are generally unable to purchase life insurance in the individual market.  If your employer offers supplemental life insurance,  you can purchase above what he or she offers; see if there is an amount you can purchase that will not require evidence of good health.

An employer may give all employees a base benefit from $10,000 to $50,000.  While some employers offer this option, many others will not.  If it is available, it is an excellent way for an otherwise “uninsurable” person to obtain additional life insurance.

Long Term Disability.  Less common, but still occasionally available, is the opportunity to increase the benefit of your LTD plan.  Some employers will provide a basic benefit for LTD, such as 50% or 60% of your monthly earnings, and allow employees to purchase an additional 10% or 15% to raise the benefit they would receive in the event of disability.

Some employers may allow you to add this benefit if you did not elect it originally. Again, it is important to read your Open Enrollment material to see if your employer offers this.

Revising LTD Premium Payment.  One additional possibility to explore is the payment of LTD premiums and its effect on the income taxability of the disability benefits should you ever need to collect them.  Some employers will allow you to have the premium for the LTD coverage added to your W-2, making the premiums taxable rather than receiving it as a tax-free gift.  If this is possible you may want to jump at the chance, the reason being taxes.

If you pay for the LTD coverage with money that is taxed as income, then the benefits you receive if you become disabled will be income tax free, substantially increasing the spendable dollars you would receive as a disability benefit.
The IRS will tax either the premium paying for the coverage or the disability benefits being paid, but not both.

Health Related Benefits.  Many employers, especially larger ones, offer a variety of health, dental, and vision plans from which employees can choose.  At Open Enrollment, you have the opportunity to change your coverage from one plan to another regardless of your medical condition, and sometimes have the opportunity to make choices within your plan, such as to increase or decrease the size of the deductible.

For someone dealing with, this can be an important choice, especially if this is the first Open Enrollment since diagnosis.  There is no one type of health plan that is best for everyone. There are two main kinds of plans that employers offer most often:

  • Preferred Provider Organization – These plans provide some coverage for all physicians, but pay more if you choose a physician that has contracted with the insurance company, a Participating Provider.  This plan will give you the greatest flexibility in medical providers; however, it will often cost you more out-of-pocket for both your portion of the monthly premium as well as the plan co-pays and co-insurance.

  • Health Maintenance Organizations – These plans usually offer the lowest out-of-pocket expenses, but limit your choice of physician. Coverage is only provided when using one of their contracting doctors and hospitals.  Also, a Primary Care Physician (also called a Gatekeeper) oversees all your medical care and must refer you to a specialist before the HMO will cover the specialist’s charge.

  • Exclusive Provider Organization – These plans are exactly like an HMO, except there is no Gatekeeper physician.  You decide if you need to see a specialist and make the appointment directly.

Which plan is better for you will depend on which doctors you wish to retain and what HMOs or PPO plans they are part of, as well as the cost to you.

Back to top

Get Tested. Get Treated. Get Cured.

Newsletter Archive

About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home


© 2014 AttorneyMind

Medical Writers' Circle
Fact Sheets